Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1011

1.

Testicular function in poor-risk nonseminomatous germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin combination chemotherapy.

Pectasides D, Pectasides E, Papaxoinis G, Skondra M, Gerostathou M, Karageorgopoulou S, Kamposioras C, Tountas N, Koumarianou A, Psyrri A, Macheras A, Economopoulos T.

J Androl. 2009 May-Jun;30(3):280-6. doi: 10.2164/jandrol.108.006437. Epub 2009 Jan 8.

2.

Testicular function in patients with testicular cancer treated with bleomycin-etoposide-carboplatin (BEC(90)) combination chemotherapy.

Pectasides D, Pectasides M, Farmakis D, Nikolaou M, Koumpou M, Kostopoulou V, Mylonakis N.

Eur Urol. 2004 Feb;45(2):187-93.

PMID:
14734005
3.

Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer.

Brennemann W, Stoffel-Wagner B, Helmers A, Mezger J, Jäger N, Klingmüller D.

J Urol. 1997 Sep;158(3 Pt 1):844-50.

PMID:
9258096
4.

Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors.

Pectasides D, Pectasides E, Papaxoinis G, Xiros N, Kamposioras K, Tountas N, Economopoulos T.

Urol Oncol. 2010 Nov-Dec;28(6):617-23. doi: 10.1016/j.urolonc.2008.10.013. Epub 2008 Dec 25.

PMID:
19110454
5.

Pretreatment follicle-stimulating hormone: a prognostic serum marker of spermatogenesis status in patients treated for germ cell cancer.

Brennemann W, Stoffel-Wagner B, Wichers M, Helmers A, Albers P, Mezger J, Klingmüller D.

J Urol. 1998 Jun;159(6):1942-6.

PMID:
9598493
6.

Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer.

Kawai K, Miyazaki J, Tsukamoto S, Hinotsu S, Hattori K, Shimazui T, Akaza H.

Jpn J Clin Oncol. 2003 Mar;33(3):127-31.

PMID:
12672789
7.

Fertility after high-dose chemotherapy for testicular cancer.

Ishikawa T, Kamidono S, Fujisawa M.

Urology. 2004 Jan;63(1):137-40.

PMID:
14751366
8.

Reproductive toxicity with and without LHRHA administration during adjuvant chemotherapy in patients with germ cell tumors.

Kreuser ED, Hetzel WD, Hautmann R, Pfeiffer EF.

Horm Metab Res. 1990 Sep;22(9):494-8.

PMID:
1701752
9.

Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.

Hartmann JT, Gauler T, Metzner B, Gerl A, Casper J, Rick O, Horger M, Schleicher J, Derigs G, Mayer-Steinacker R, Beyer J, Kuczyk MA, Bokemeyer C; German Testicular Cancer Study Group.

J Clin Oncol. 2007 Dec 20;25(36):5742-7.

PMID:
18089869
10.

Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors.

Nonomura N, Oka D, Nishimura K, Nakayama M, Inoue H, Mizutani Y, Miki T, Okuyama A.

Int J Urol. 2007 Jun;14(6):527-31.

11.

The effects of etoposide on testicular function in boys treated for Hodgkin's disease.

Gerres L, Brämswig JH, Schlegel W, Jürgens H, Schellong G.

Cancer. 1998 Nov 15;83(10):2217-22.

PMID:
9827728
12.

The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors.

Gerl A, Mühlbayer D, Hansmann G, Mraz W, Hiddemann W.

Cancer. 2001 Apr 1;91(7):1297-303.

PMID:
11283930
13.

Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.

Tryakin A, Fedyanin M, Kanagavel D, Fainstein I, Sergeev J, Polockij B, Matveev V, Zakharova T, Garin A, Tjulandin S.

Urology. 2011 Sep;78(3):620-5. doi: 10.1016/j.urology.2011.05.005. Epub 2011 Jul 20.

PMID:
21764427
14.

Pituitary and testicular hormonal function after treatment for germ cell tumours.

Bosl GJ, Bajorunas D.

Int J Androl. 1987 Feb;10(1):381-4.

PMID:
2438229
16.

Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.

Park S, Lee S, Lee J, Park SH, Park JO, Kang WK, Park YS, Lim HY.

Onkologie. 2011;34(8-9):416-20. doi: 10.1159/000331129. Epub 2011 Aug 23.

PMID:
21934340
17.

Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.

Westermann DH, Schefer H, Thalmann GN, Karamitopoulou-Diamantis E, Fey MF, Studer UE.

J Urol. 2008 Jan;179(1):163-6. Epub 2007 Nov 14.

PMID:
18001800
19.

Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.

Culine S, Kramar A, Théodore C, Geoffrois L, Chevreau C, Biron P, Nguyen BB, Héron JF, Kerbrat P, Caty A, Delva R, Fargeot P, Fizazi K, Bouzy J, Droz JP; Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.

J Clin Oncol. 2008 Jan 20;26(3):421-7. doi: 10.1200/JCO.2007.13.8461.

PMID:
18202419
20.

Supplemental Content

Support Center